Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published Date:

Abstract

INTRODUCTION: Pathologic response (PathR) by histopathologic assessment of resected specimens may be an early clinical end point associated with long-term outcomes with neoadjuvant therapy. Digital pathology may improve the efficiency and precision of PathR assessment. LCMC3 (NCT02927301) evaluated neoadjuvant atezolizumab in patients with resectable NSCLC and reported a 20% major PathR rate.

Authors

  • Sanja Dacic
    FISH and Developmental Laboratory at the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • William D Travis
    Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York.
  • Jennifer M Giltnane
    Research Pathology, Genentech, Inc., South San Francisco, California.
  • Filip Kos
    Department of Machine Learning, PathAI, Inc., Boston, Massachusetts.
  • John Abel
    Department of Machine Learning, PathAI, Inc., Boston, Massachusetts.
  • Stephanie Hilz
    Research Pathology, Genentech, Inc., South San Francisco, California.
  • Junya Fujimoto
    Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Lynette Sholl
    Department of Anatomic Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Jon Ritter
    Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
  • Farah Khalil
    Department of Pathology, Moffitt Cancer Center, Tampa, Florida.
  • Yi Liu
    Department of Interventional Therapy, Ningbo No. 2 Hospital, Ningbo, China.
  • Amaro Taylor-Weiner
    Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge.
  • Murray Resnick
    PathAI, Boston, MA.
  • Hui Yu
    Engineering Technology Research Center of Shanxi Province for Opto-Electric Information and Instrument, Taiyuan 030051, China. 13934603474@nuc.edu.cn.
  • Fred R Hirsch
    Department of Hematology and Medical Oncology, University of Colorado/Icahn School of Medicine, Mount Sinai, New York.
  • Paul A Bunn
    Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • David P Carbone
    Division of Medical Oncology, The Ohio State University Medical Center and Pelotonia Institute for Immuno-Oncology, Columbus, Ohio.
  • Valerie Rusch
    Memorial Sloan Kettering Cancer Center, Department of Thoracic Surgery, New York, New York.
  • David J Kwiatkowski
    Department of Anatomic Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Bruce E Johnson
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Jay M Lee
    Division of Thoracic Surgery, University of California, Los Angeles, Los Angeles, California.
  • Stephanie R Hennek
    Department of Translational Research, PathAI, Inc., Boston, Massachusetts.
  • Ilan Wapinski
    PathAI, Boston, MA.
  • Alan Nicholas
    U.S. Medical Affairs, Genentech, Inc., South San Francisco, California.
  • Ann Johnson
    U.S. Medical Affairs, Genentech, Inc., South San Francisco, California.
  • Katja Schulze
    Oculyze GmbH, Mobile Microscopy and Computer Vision, Wildau, Germany.
  • Mark G Kris
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ignacio I Wistuba
    Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX.